Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer

Pooja Patel, James C. Yao, Kenneth Hess, Isac Schnirer, Asif Rashid, Jaffer A. Ajani

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

BACKGROUND. Patients with advanced gastric cancer have a median survival (MS) of <9 months. It is unclear whether the MS of patients who have advanced cancer at the time of diagnosis (synchronous, Group A) is different from that for patients who develop advanced cancer after curative surgery (metachronous, Group B). It was hypothesized that survival would be similar. METHODS. The medical records of all patients treated at the University of Texas M. D. Anderson Cancer Center who were in either Group A or Group B were reviewed. Survival of patients was assessed by the Kaplan-Meier method. A Cox proportional hazards model was used for multivariate hazards ratios that were adjusted for the effects of location of recurrence, histologic differentiation, patient sex and age, the location of the primary tumor, and timing of disease recurrence (Group A or Group B) on survival. RESULTS. In all, 773 consecutive patients qualified for the analysis. The distribution of age, race, histologic differentiation, and primary tumor location was similar in both groups. The MS of Group A (n = 603 patients) and Group B (n = 170 patients) was the same (7.6 months). Similarly, the location of the primary tumor and patient sex were found to have no impact on survival. Patients with poorly differentiated tumors (World Health Organization grade 3 or 4) were found to have a shorter survival compared with those with well-differentiated or moderately differentiated tumors (grade 1 or 2; P = .004). Patients with distant metastases had a shorter survival (P = .01) than those with locoregional disease recurrence. CONCLUSIONS. The data show that MS is similarly poor in patients with advanced gastric cancer with synchronous metastasis (Group A) or those with metachronous metastasis/disease recurrence (Group B). Poor differentiation and anatomically distant site of metastasis were found to impact MS adversely.

Original languageEnglish (US)
Pages (from-to)2186-2190
Number of pages5
JournalCancer
Volume110
Issue number10
DOIs
StatePublished - Nov 15 2007
Externally publishedYes

Fingerprint

Stomach Neoplasms
Neoplasm Metastasis
Recurrence
Survival
Neoplasms
Sex Differentiation
Age Distribution
Proportional Hazards Models
Medical Records

Keywords

  • Median survival
  • Metachronous metastases
  • Stomach neoplasms
  • Synchronous metastases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. / Patel, Pooja; Yao, James C.; Hess, Kenneth; Schnirer, Isac; Rashid, Asif; Ajani, Jaffer A.

In: Cancer, Vol. 110, No. 10, 15.11.2007, p. 2186-2190.

Research output: Contribution to journalArticle

Patel, Pooja ; Yao, James C. ; Hess, Kenneth ; Schnirer, Isac ; Rashid, Asif ; Ajani, Jaffer A. / Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. In: Cancer. 2007 ; Vol. 110, No. 10. pp. 2186-2190.
@article{4e61f23f86084e01812e2d32c871b6c9,
title = "Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer",
abstract = "BACKGROUND. Patients with advanced gastric cancer have a median survival (MS) of <9 months. It is unclear whether the MS of patients who have advanced cancer at the time of diagnosis (synchronous, Group A) is different from that for patients who develop advanced cancer after curative surgery (metachronous, Group B). It was hypothesized that survival would be similar. METHODS. The medical records of all patients treated at the University of Texas M. D. Anderson Cancer Center who were in either Group A or Group B were reviewed. Survival of patients was assessed by the Kaplan-Meier method. A Cox proportional hazards model was used for multivariate hazards ratios that were adjusted for the effects of location of recurrence, histologic differentiation, patient sex and age, the location of the primary tumor, and timing of disease recurrence (Group A or Group B) on survival. RESULTS. In all, 773 consecutive patients qualified for the analysis. The distribution of age, race, histologic differentiation, and primary tumor location was similar in both groups. The MS of Group A (n = 603 patients) and Group B (n = 170 patients) was the same (7.6 months). Similarly, the location of the primary tumor and patient sex were found to have no impact on survival. Patients with poorly differentiated tumors (World Health Organization grade 3 or 4) were found to have a shorter survival compared with those with well-differentiated or moderately differentiated tumors (grade 1 or 2; P = .004). Patients with distant metastases had a shorter survival (P = .01) than those with locoregional disease recurrence. CONCLUSIONS. The data show that MS is similarly poor in patients with advanced gastric cancer with synchronous metastasis (Group A) or those with metachronous metastasis/disease recurrence (Group B). Poor differentiation and anatomically distant site of metastasis were found to impact MS adversely.",
keywords = "Median survival, Metachronous metastases, Stomach neoplasms, Synchronous metastases",
author = "Pooja Patel and Yao, {James C.} and Kenneth Hess and Isac Schnirer and Asif Rashid and Ajani, {Jaffer A.}",
year = "2007",
month = "11",
day = "15",
doi = "10.1002/cncr.23046",
language = "English (US)",
volume = "110",
pages = "2186--2190",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer

AU - Patel, Pooja

AU - Yao, James C.

AU - Hess, Kenneth

AU - Schnirer, Isac

AU - Rashid, Asif

AU - Ajani, Jaffer A.

PY - 2007/11/15

Y1 - 2007/11/15

N2 - BACKGROUND. Patients with advanced gastric cancer have a median survival (MS) of <9 months. It is unclear whether the MS of patients who have advanced cancer at the time of diagnosis (synchronous, Group A) is different from that for patients who develop advanced cancer after curative surgery (metachronous, Group B). It was hypothesized that survival would be similar. METHODS. The medical records of all patients treated at the University of Texas M. D. Anderson Cancer Center who were in either Group A or Group B were reviewed. Survival of patients was assessed by the Kaplan-Meier method. A Cox proportional hazards model was used for multivariate hazards ratios that were adjusted for the effects of location of recurrence, histologic differentiation, patient sex and age, the location of the primary tumor, and timing of disease recurrence (Group A or Group B) on survival. RESULTS. In all, 773 consecutive patients qualified for the analysis. The distribution of age, race, histologic differentiation, and primary tumor location was similar in both groups. The MS of Group A (n = 603 patients) and Group B (n = 170 patients) was the same (7.6 months). Similarly, the location of the primary tumor and patient sex were found to have no impact on survival. Patients with poorly differentiated tumors (World Health Organization grade 3 or 4) were found to have a shorter survival compared with those with well-differentiated or moderately differentiated tumors (grade 1 or 2; P = .004). Patients with distant metastases had a shorter survival (P = .01) than those with locoregional disease recurrence. CONCLUSIONS. The data show that MS is similarly poor in patients with advanced gastric cancer with synchronous metastasis (Group A) or those with metachronous metastasis/disease recurrence (Group B). Poor differentiation and anatomically distant site of metastasis were found to impact MS adversely.

AB - BACKGROUND. Patients with advanced gastric cancer have a median survival (MS) of <9 months. It is unclear whether the MS of patients who have advanced cancer at the time of diagnosis (synchronous, Group A) is different from that for patients who develop advanced cancer after curative surgery (metachronous, Group B). It was hypothesized that survival would be similar. METHODS. The medical records of all patients treated at the University of Texas M. D. Anderson Cancer Center who were in either Group A or Group B were reviewed. Survival of patients was assessed by the Kaplan-Meier method. A Cox proportional hazards model was used for multivariate hazards ratios that were adjusted for the effects of location of recurrence, histologic differentiation, patient sex and age, the location of the primary tumor, and timing of disease recurrence (Group A or Group B) on survival. RESULTS. In all, 773 consecutive patients qualified for the analysis. The distribution of age, race, histologic differentiation, and primary tumor location was similar in both groups. The MS of Group A (n = 603 patients) and Group B (n = 170 patients) was the same (7.6 months). Similarly, the location of the primary tumor and patient sex were found to have no impact on survival. Patients with poorly differentiated tumors (World Health Organization grade 3 or 4) were found to have a shorter survival compared with those with well-differentiated or moderately differentiated tumors (grade 1 or 2; P = .004). Patients with distant metastases had a shorter survival (P = .01) than those with locoregional disease recurrence. CONCLUSIONS. The data show that MS is similarly poor in patients with advanced gastric cancer with synchronous metastasis (Group A) or those with metachronous metastasis/disease recurrence (Group B). Poor differentiation and anatomically distant site of metastasis were found to impact MS adversely.

KW - Median survival

KW - Metachronous metastases

KW - Stomach neoplasms

KW - Synchronous metastases

UR - http://www.scopus.com/inward/record.url?scp=36049041592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36049041592&partnerID=8YFLogxK

U2 - 10.1002/cncr.23046

DO - 10.1002/cncr.23046

M3 - Article

VL - 110

SP - 2186

EP - 2190

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -